BidaskClub lowered shares of Cambrex Corporation (NYSE:CBM) from a buy rating to a hold rating in a research report sent to investors on Saturday.
Several other brokerages have also issued reports on CBM. Zacks Investment Research raised Cambrex Corporation from a hold rating to a buy rating and set a $59.00 price objective on the stock in a report on Thursday, May 11th. ValuEngine lowered Cambrex Corporation from a buy rating to a hold rating in a report on Friday, June 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $64.00.
Cambrex Corporation (NYSE CBM) opened at 53.15 on Friday. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The company’s 50-day moving average price is $58.05 and its 200 day moving average price is $55.50. The stock has a market capitalization of $1.74 billion, a P/E ratio of 19.36 and a beta of 2.28.
Cambrex Corporation (NYSE:CBM) last posted its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.76. The company had revenue of $134.55 million for the quarter, compared to analysts’ expectations of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. Cambrex Corporation’s quarterly revenue was up 13.4% on a year-over-year basis. During the same period last year, the firm earned $0.68 earnings per share. Equities research analysts expect that Cambrex Corporation will post $3.08 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/08/16/cambrex-corporation-cbm-cut-to-hold-at-bidaskclub.html.
In other Cambrex Corporation news, VP Samantha Hanley sold 14,000 shares of Cambrex Corporation stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $57.56, for a total value of $805,840.00. Following the sale, the vice president now owns 1,500 shares of the company’s stock, valued at approximately $86,340. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $61.39, for a total value of $736,680.00. Following the completion of the sale, the chief executive officer now directly owns 95,328 shares in the company, valued at approximately $5,852,185.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 70,656 shares of company stock worth $4,064,423. Corporate insiders own 2.48% of the company’s stock.
A number of large investors have recently made changes to their positions in CBM. Flinton Capital Management LLC raised its stake in shares of Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares in the last quarter. Creative Planning raised its stake in shares of Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after buying an additional 150 shares in the last quarter. YorkBridge Wealth Partners LLC raised its stake in shares of Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Cambrex Corporation during the first quarter worth $109,000. 98.28% of the stock is currently owned by institutional investors.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
